FORMULATION AND INVITRO EVALUATION OF ALDOPHOSPHAMIDE NANOPARTICLES USING CHITOSAN POLYMER

Madiboina Gnanadeepika
Department of Pharmaceutics, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore-524346, Andhra Pradesh, India
Manasa E
Department of Pharmacognosy & Phytochemistry, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore-524346, Andhra Pradesh, India
Avinash Kumar G
Department of Pharmacognosy & Phytochemistry, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore-524346, Andhra Pradesh, India
Divya E
Department of Pharmaceutics, Sun Institute of Pharmaceutical Education and Research, Kakupalli, Nellore-524346, Andhra Pradesh, India

Aldophosphamide, Gelatin, Prostate Cancer, Nanoparticles ,

The development of innovative treatment modalities has become a significant health challenge globally due to the prevalence of prostate cancer. Aldophosphamide-loaded gelatin nanoparticles are examined in this study as a promising approach for delivering targeted therapy to prostate cancer patients. Gelatin, a biocompatible and biodegradable polymer, was utilized as the matrix for nanoparticles due to its favorable properties for drug delivery. An anticancer agent known for its potent properties is aldophosphamide, a derivative of cyclophosphamide. A variety of physicochemical properties of the nanoparticles, such as size, morphology, and drug loading efficiency, were determined using dynamic light scattering, scanning electron microscopy, and ultraviolet spectroscopy. Aldophosphamide was consistently released from the nanoparticles during prolonged in vitro studies, suggesting their potential to exert a prolonged therapeutic effect. A study of cellular uptake of the nanoparticles using prostate cancer cell lines demonstrated efficient internalization of the particles, further verifying their potential for drug delivery. According to our studies, Aldophosphamide-loaded gelatin nanoparticles offer enhanced therapeutic efficacy, sustained release kinetics, and targeted drug delivery for prostate cancer treatment

14 , 1 , 2024